-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

Benzinga·07/15/2025 15:04:22
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains the price target from $35 to $35.